Table 4.
Incidence and severity of AEs in the 21 days following the initiation of intensive pegcetacoplan treatment
| Patients (N = 13) | |
|---|---|
| Patients with ≥1 AE, n (%) | 7 (54) |
| Total AEs, n (%) | 22 |
| Mild | 13 (59) |
| Moderate | 4 (18) |
| Severe | 5 (23) |
| Related to PEG | 10 (45) |
| AEs during intensive dosing, n (%) | 4 (18) |
| Mild | 3 (14) |
| Moderate | 0 |
| Severe | 1 (5) |
| Related to PEG | 2 (9) |
| Serious AEs, n (%) | 3 (14) |
| Related to PEG | 1 (5) |
| AEs leading to treatment discontinuation, n (%) | 0 |
| AEs leading to death, n (%) | 0 |
| AEs by preferred term, n | |
| Infusion site erythema | 7 |
| Hemolysis | 5 |
| Increased LDH | 2 |
| Anemia | 1 |
| Blood creatinine increased | 1 |
| CRP increased | 1 |
| Chest discomfort | 1 |
| Headache | 1 |
| Infusion site induration | 1 |
| Pyrexia | 1 |
| Sepsis | 1 |
| AEs of interest | |
| Infection | 1 |
| Thrombosis | 0 |
AE, adverse event; CRP, C-reactive protein; LDH, lactate dehydrogenase; PEG, pegcetacoplan; SAE, serious adverse event.